Anders Palmstrøm Jørgensen

• Havnes, Ingrid Amalia; Henriksen, Hans Christian Bordado; Johansen, Per Wiik; Bjørnebekk, Astrid Kristine; Neupane, Sudan Prasad & Hisdal, Jonny [Show all 11 contributors for this article] (2024). Off-label use of clomiphene citrate to treat anabolic androgenic steroid induced hypogonadism upon cessation among men (CloTASH) – A pilot study protocol. MethodsX. ISSN 2215-0161. 13. doi: 10.1016/j.mex.2024.102810.
• Henriksen, Hans Christian Bordado; Jørgensen, Anders Palmstrøm; Bjørnebekk, Astrid Kristine; Neupane, Sudan Prasad & Havnes, Ingrid Amalia (2024). Clomiphene citrate and optional human chorionic gonadotropin for treating male hypogonadism arising from long-term anabolic-androgenic steroid use—A pilot study. Performance Enhancement & Health. ISSN 2211-2669. doi: 10.1016/j.peh.2024.100283.
• Sjøgren, Thea; islam, shahinul; Filippov, Igor; Jebrzycka, Adrianna; Sulen, André & Breivik, Lars Ertesvåg [Show all 16 contributors for this article] (2024). Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1. iScience. ISSN 2589-0042. 27(4). doi: 10.1016/j.isci.2024.109610.
• Sævik, Åse Bjorvatn; Ueland, Grethe Åstrøm; Åkerman, Anna-Karin; Methlie, Paal; Quinkler, Marcus & Jørgensen, Anders Palmstrøm [Show all 26 contributors for this article] (2023). Altered biomarkers for cardiovascular disease and inflammation in autoimmune Addison's disease - a cross-sectional study. European Journal of Endocrinology (EJE). ISSN 0804-4643. 189(4), p. 438–447. doi: 10.1093/ejendo/lvad136. Full text in Research Archive Show summary

  Increased prevalence of cardiovascular disease has been reported in autoimmune Addison's disease (AAD), but pathomechanisms are poorly understood. Design Cross-sectional study. Methods We compared serum levels of 177 cardiovascular and inflammatory biomarkers in 43 patients with AAD at >18-h glucocorticoid withdrawal and 43 matched controls, overall and stratified for sex. Biomarker levels were correlated with the frequency of adrenal crises and quality of life (QoL) by AddiQoL-30. Finally, we investigated changes in biomarker levels following 250 µg tetracosactide injection in patients without residual adrenocortical function (RAF) to explore glucocorticoid-independent effects of high ACTH. Results Nineteen biomarkers significantly differed between patients with AAD and controls; all but 1 (ST1A1) were higher in AAD. Eight biomarkers were significantly higher in female patients compared with controls (IL6, MCP1, GAL9, SPON2, DR4, RAGE, TNFRSF9, and PGF), but none differed between male patients and controls. Levels of RAGE correlated with the frequency of adrenal crises (r = 0.415, P = .006) and AddiQoL-30 scores (r = −0.347, P = .028) but not after correction for multiple testing. PDL2 and leptin significantly declined 60 min after injection of ACTH in AAD without RAF (−0.15 normalized protein expression [NPX], P = .0001, and −0.25 NPX, P = .0003, respectively). Conclusions We show that cardiovascular and inflammatory biomarkers are altered in AAD compared with controls, particularly in women. RAGE might be a marker of disease severity in AAD, associated with more adrenal crises and reduced QoL. High ACTH reduced PDL2 and leptin levels in a glucocorticoid-independent manner but the overall effect on biomarker profiles was small.

• Henriksen, Hans Christian Bordado; Jørgensen, Anders Palmstrøm; Wisløff, Christine & Havnes, Ingrid Amalia (2023). Challenges recruiting men with a desire to cease anabolic-androgenic steroid use to a pilot involving hormone therapy intervention. Drugs: education prevention and policy. ISSN 0968-7637. doi: 10.1080/09687637.2023.2244655. Full text in Research Archive
• Wolff, Anette Susanne Bøe; Hansen, Lena; Grytaas, Marianne Aardal; Oftedal, Bergithe Eikeland; Breivik, Lars Ertesvåg & Zhou, Fan [Show all 17 contributors for this article] (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. ISSN 2589-0042. 26(7). doi: 10.1016/j.isci.2023.107084.
• Aranda-Guillén, Maribel; Røyrvik, Ellen Christine; Fletcher-Sandersjöö, Sara; Artaza, Haydee; Botusan, Ileana Ruxandra & Grytaas, Marianne A. [Show all 18 contributors for this article] (2023). A polygenic risk score to help discriminate primary adrenal insufficiency of different etiologies. Journal of Internal Medicine. ISSN 0954-6820. 294(1), p. 96–109. doi: 10.1111/joim.13649.
• Åkerman, Anna-Karin; Sævik, Åse Bjorvatn; Thorsby, Per Medbøe; Methlie, Paal; Quinkler, Marcus & Jørgensen, Anders Palmstrøm [Show all 26 contributors for this article] (2023). Plasma-Metanephrines in Patients with Autoimmune Addison’s Disease with and without Residual Adrenocortical Function. Journal of Clinical Medicine. ISSN 2077-0383. 12:3602(10), p. 1–10. doi: 10.3390/jcm12103602. Full text in Research Archive Show summary

  Purpose: Residual adrenocortical function, RAF, has recently been demonstrated in one-third of patients with autoimmune Addison's disease (AAD). Here, we set out to explore any influence of RAF on the levels of plasma metanephrines and any changes following stimulation with cosyntropin. Methods: We included 50 patients with verified RAF and 20 patients without RAF who served as controls upon cosyntropin stimulation testing. The patients had abstained from glucocorticoid and fludrocortisone replacement > 18 and 24 h, respectively, prior to morning blood sampling. The samples were obtained before and 30 and 60 min after cosyntropin stimulation and analyzed for serum cortisol, plasma metanephrine (MN), and normetanephrine (NMN) by liquid-chromatography tandem-mass pectrometry (LC-MS/MS). Results: Among the 70 patients with AAD, MN was detectable in 33%, 25%, and 26% at baseline, 30 min, and 60 min after cosyntropin stimulation, respectively. Patients with RAF were more likely to have detectable MN at baseline (p = 0.035) and at the time of 60 min (p = 0.048) compared to patients without RAF. There was a positive correlation between detectable MN and the level of cortisol at all time points (p = 0.02, p = 0.04, p < 0.001). No difference was noted for NMN levels, which remained within the normal reference ranges. Conclusion: Even very small amounts of endogenous cortisol production affect MN levels in patients with AAD.

• Kolnes, Anders Jensen; Øystese, Kristin Astrid Berland; Sjöstedt, Evelina; Olarescu, Nicoleta Cristina; Heck, Ansgar & Pahnke, Jens [Show all 12 contributors for this article] (2023). TGFBR3L is associated with gonadotropin production in non-functioning gonadotroph pituitary neuroendocrine tumours. Pituitary. ISSN 1386-341X. 26, p. 227–236. doi: 10.1007/s11102-023-01310-x. Full text in Research Archive
• Stokland, Ann-Elin Meling; Ueland, Grethe Åstrøm; Lima, Kari; Grønning, Kaja; Finnes, Trine Elisabeth & Svendsen, Margrethe [Show all 22 contributors for this article] (2022). Autoimmune Thyroid Disorders in Autoimmune Addison Disease. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 107(6), p. e2331–e2338. doi: 10.1210/clinem/dgac089. Full text in Research Archive Show summary

  Context: Autoimmune thyroid disease is the most common endocrine co-morbidity in autoimmune Addison's disease (AAD), but detailed investigations of prevalence and clinical course is lacking. Objective: Provide comprehensive epidemiological and clinical data on autoimmune thyroid disorders in AAD. Design and patients: A nationwide registry-based study including 442 patients with AAD and autoimmune thyroid disease, identified through the Norwegian National Registry of Autoimmune Diseases. Results: Of 912 registered AAD patients, 442 (48%) were diagnosed with autoimmune thyroid disease. Three hundred and eighty (42%) had autoimmune hypothyroidism. Of the 302 with available thyroid function tests at time for diagnosis, 20% had overt hypothyroidism, 73% had subclinical hypothyroidism and 7% had thyroid levels in the normal range. Negative thyroid peroxidase antibodies was found in 32%. Ninety-eight percent were treated with levothyroxine, 5% with combination therapy with liothyronine or thyroid extracts, and 1% were observed without treatment. Seventy-eight patients (9%) were diagnosed with Graves' disease (GD), of whom 16 (21%) were diagnosed with autoimmune hypothyroidism either before onset or after remission of GD. At the end of follow-up 33% had normal thyroid hormone levels without antithyroid-drugs or levothyroxine treatment. The remaining had either active disease (5%), had undergone ablative treatment (41%), or had developed autoimmune hypothyroidism (21%). Conclusion: The true prevalence of hypothyroidism in AAD is lower than reported in current literature. Careful consideration of the indication to start thyroxin therapy is warranted. Long-term remission rates in GD patients with AAD are comparable to recent reports on long-term follow-up of patients without AAD.

• Shukur, Hasanain Hamid; Hussain-Alkhateeb, Laith; Farholt, Stense; Nørregaard, Ole; Jørgensen, Anders Palmstrøm & Hoybye, Charlotte (2021). Effects of Growth Hormone Treatment on Sleep-Related Parameters in Adults with Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 106(9), p. E3634–E3643. doi: 10.1210/clinem/dgab300.
• Jørgensen, Anders Palmstrøm (2021). Endocrine Workup for Primary Aldosteronism Should Include Adrenal Venous Sampling in Young Patients. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 106(7), p. e2828–e2829. doi: 10.1210/clinem/dgab142.
• Eriksson, Daniel; Røyrvik, Ellen Christine; Aranda-Guillen, Maribel; Berger, Amund Holte; Landegren, Nils & Alvarez, Haydee Maribel Artaza [Show all 30 contributors for this article] (2021). GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nature Communications. ISSN 2041-1723. 12:959, p. 1–14. doi: 10.1038/s41467-021-21015-8. Full text in Research Archive Show summary

  Autoimmune Addison’s disease (AAD) is characterized by the autoimmune destruction of the adrenal cortex. Low prevalence and complex inheritance have long hindered successful genetic studies. We here report the first genome-wide association study on AAD, which identifies nine independent risk loci (P < 5 × 10−8). In addition to loci implicated in lymphocyte function and development shared with other autoimmune diseases such as HLA, BACH2, PTPN22 and CTLA4, we associate two protein-coding alterations in Autoimmune Regulator (AIRE) with AAD. The strongest, p.R471C (rs74203920, OR = 3.4 (2.7–4.3), P = 9.0 × 10−25) introduces an additional cysteine residue in the zinc-finger motif of the second PHD domain of the AIRE protein. This unbiased elucidation of the genetic contribution to development of AAD points to the importance of central immunological tolerance, and explains 35–41% of heritability (h2).

• Sjöstedt, Evelina; Kolnes, Anders Jensen; Olarescu, Nicoleta Cristina; Mitsios, Nicholas; Hikmet, Feria & Sivertsson, Åsa [Show all 11 contributors for this article] (2021). Tgfbr3l—an uncharacterised pituitary specific membrane protein detected in the gonadotroph cells in non-neoplastic and tumour tissue. Cancers. ISSN 2072-6694. 13:114(1), p. 1–15. doi: 10.3390/CANCERS13010114. Full text in Research Archive
• Kolnes, Anders Jensen; Øystese, Kristin Astrid; Dahlberg, Daniel; Berg-Johnsen, Jon; Niehusmann, Pitt & Pahnke, Jens [Show all 8 contributors for this article] (2020). Cut-off values for sufficient cortisol response to low dose Short Synacthen Test after surgery for non-functioning pituitary adenoma. Acta Neurochirurgica. ISSN 0001-6268. 162(4), p. 845–852. doi: 10.1007/s00701-019-04068-z. Full text in Research Archive
• Kolnes, Anders Jensen; Øystese, Kristin Astrid; Olarescu, Nicoleta Cristina; Ringstad, Geir Andre; Berg-Johnsen, Jon & Casar-Borota, Olivera [Show all 8 contributors for this article] (2020). FSH Levels Are Related to E-cadherin Expression and Subcellular Location in Nonfunctioning Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 105(8), p. 1–8. doi: 10.1210/clinem/dgaa281. Full text in Research Archive
• Sævik, Åse Bjorvatn; Åkerman, Anna-Karin; Methlie, Paal; Quinkler, Marcus; Jørgensen, Anders Palmstrøm & Høybye, Charlotte [Show all 26 contributors for this article] (2020). Residual Corticosteroid Production in Autoimmune Addison Disease. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 105(7), p. 2430–2441. doi: 10.1210/clinem/dgaa256. Full text in Research Archive Show summary

  Design: Two-staged, cross-sectional clinical study in 17 centers (Norway, Sweden, and Germany). Residual glucocorticoid (GC) production was defined as quantifiable serum cortisol and 11-deoxycortisol and residual mineralocorticoid (MC) production as quantifiable serum aldosterone and corticosterone after > 18 hours of medication fasting. Corticosteroids were analyzed by liquid chromatography–tandem mass spectrometry. Clinical variables included frequency of adrenal crises and quality of life. Peak cortisol response was evaluated by a standard 250 µg cosyntropin test. Results: Fifty-eight (30.2%) of 192 patients had residual GC production, more common in men (n = 33; P < 0.002) and in shorter disease duration (median 6 [0-44] vs 13 [0-53] years; P < 0.001). Residual MC production was found in 26 (13.5%) patients and associated with shorter disease duration (median 5.5 [0.5-26.0] vs 13 [0-53] years; P < 0.004), lower fludrocortisone replacement dosage (median 0.075 [0.050-0.120] vs 0.100 [0.028-0.300] mg; P < 0.005), and higher plasma renin concentration (median 179 [22-915] vs 47.5 [0.6-658.0] mU/L; P < 0.001). There was no significant association between residual production and frequency of adrenal crises or quality of life. None had a normal cosyntropin response, but peak cortisol strongly correlated with unstimulated cortisol (r = 0.989; P < 0.001) and plasma adrenocorticotropic hormone (ACTH; r = –0.487; P < 0.001). Conclusion: In established AAD, one-third of the patients still produce GCs even decades after diagnosis. Residual production is more common in men and in patients with shorter disease duration but is not associated with adrenal crises or quality of life. (J Clin Endocrinol Metab 105: 1–12, 2020) Key words: Adrenal failure; adrenal steroids; Autoimmune Addison disease; cortisol; primary adrenal insufficiency; residual function

• Sævik, Åse Bjorvatn; Åkerman, Anna Karin; Grønning, Kaja; Nermoen, Ingrid; Valland, Susanna Fonneland & Finnes, Trine Elisabeth [Show all 22 contributors for this article] (2017). Clues for early detection of autoimmune Addison's disease - myths and realities. Journal of Internal Medicine. ISSN 0954-6820. 283(2), p. 190–199. doi: 10.1111/joim.12699.
• Tazmini, Kiarash; Meling, Torstein Ragnar; Skattør, Thor Håkon; Jørstad, Øystein Kalsnes & Jørgensen, Anders Palmstrøm (2017). A woman in her 50s with chronic fatigue syndrome, sepsis and hyponatraemia. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 137(5), p. 372–377. doi: 10.4045/tidsskr.16.0896.
• Bruserud, Øyvind; Oftedal, Bergithe Eikeland; Landegren, Nils; Erichsen, Martina Moter; Bratland, Eirik & Lima, Kari [Show all 21 contributors for this article] (2016). A longitudinal follow-up of autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 101(8), p. 2975–2983. doi: 10.1210/jc.2016-1821. Full text in Research Archive
• Ueland, Thor; Olarescu, Nicoleta Cristina; Jørgensen, Anders Palmstrøm; Otterdal, Kari; Aukrust, Pål & Godang, Kristin [Show all 8 contributors for this article] (2015). Increased serum and bone matrix levels of the secreted Wnt antagonist DKK-1 in patients with growth hormone deficiency in response to growth hormone treatment. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 100(2), p. 736–743. doi: 10.1210/jc.2014-2912.
• Olarescu, Nicoleta Cristina; Jørgensen, Anders Palmstrøm; Godang, Kristin; Jurik, Anne Grethe; Frøslie, Kathrine Frey & Bollerslev, Jens (2014). Dual-energy X-ray absorptiometry is a valid method to estimate visceral adipose tissue in adult patients with Prader-Willi syndrome during treatment with growth hormone. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 99(9), p. E1727–E1731. doi: 10.1210/jc.2014-2059.
• Jørgensen, Anders Palmstrøm; Ueland, Thor; Sode-Carlsen, Rasmus; Schreiner, Thomas; Rabben, Kai Fr. & Farholt, Stense [Show all 9 contributors for this article] (2014). Glucose homeostasis in adults with Prader-Willi syndrome during treatment with growth hormone: Results from a 12-month prospective study. Growth Hormone & IGF Research. ISSN 1096-6374. 24(1), p. 16–21. doi: 10.1016/j.ghir.2013.11.002.
• Jørgensen, Anders Palmstrøm; Ueland, Thor; Sode-Carlsen, Rasmus; Schreiner, Thomas; Rabben, Kai Fr. & Farholt, S. [Show all 9 contributors for this article] (2013). Two Years of Growth Hormone Treatment in Adults With Prader-Willi Syndrome Do Not Improve the Low BMD. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 98(4), p. E753–E760. doi: 10.1210/jc.2012-3378.
• Ueland, Thor; Lekva, Tove; Otterdal, Kari; Dahl, Tuva Børresdatter; Olarescu, Nicoleta Cristina & Jørgensen, Anders Palmstrøm [Show all 10 contributors for this article] (2011). Increased serum and bone matrix levels of transforming growth factor beta 1 in patients with GH deficiency in response to GH treatment. European Journal of Endocrinology (EJE). ISSN 0804-4643. 165(3), p. 393–400. doi: 10.1530/EJE-11-0442.
• Jørgensen, Anders Palmstrøm; Fougner, Kristian J; Ueland, Thor; Gudmundsen, Ola; Burman, Pia & Schreiner, Thomas [Show all 7 contributors for this article] (2011). Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Hormone & IGF Research. ISSN 1096-6374. 21(2), p. 69–75. doi: 10.1016/j.ghir.2011.01.001.
• Ueland, Thor; Jørgensen, Anders Palmstrøm; Godang, Kristin; Fougner, Kristian J; Aukrust, Pål & Burman, Pia [Show all 7 contributors for this article] (2011). Interleukin 1 receptor antagonist is associated with changes in body composition during physiological GH substitution in patients with adult-onset growth hormone deficiency. Clinical Endocrinology. ISSN 0300-0664. 74(1), p. 60–66. doi: 10.1111/j.1365-2265.2010.03884.x.
• Bollerslev, Jens; Hallén, Jostein; Fougner, Kristian J; Jørgensen, Anders Palmstrøm; Kristo, Cybele & Fagertun, Hans [Show all 9 contributors for this article] (2005). Low-dose GH improves exercise capacity in adults with GH deficiency : effects of a 22-month placebo-controlled, crossover trial. European Journal of Endocrinology (EJE). ISSN 0804-4643. 153(3), p. 379–387. Show summary

  Fifty-five patients with adult-onset GH deficiency (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life (QOL). GH and placebo were administered for 9 months each, separated by a 4-month washout period. GH therapy was individually dosed to obtain an IGF-I concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for men and 1.8 IU/day for women. Mean IGF-I concentration at baseline was higher in men than in women (95+/-33 vs 68+/-41 microg/l respectively; P < 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9+/-2.9 kg and lean body mass was increased by 1.8+/-2.8 kg (P = 0.0001 for each) with GH treatment. Total and low-density cholesterol levels decreased. Absolute maximal oxygen uptake increased by 6% (P = 0.01), relative to body weight by 9% (P = 0.004), and there was a trend toward increased endurance performance by 7% (P = 0.07). There were no significant effects on QOL. In conclusion, treatment with a low, physiologic dose of GH produced positive effects on body composition and lipids and improved exercise capacity, likely to be of clinical relevance. No changes in QOL were seen, possibly because of a good QOL at baseline.

View all works in Cristin

• Jørgensen, Anders Palmstrøm & Bollerslev, Jens (2012). BONE Growth hormone replacement-implications for bone health. Nature Reviews Endocrinology. ISSN 1759-5029. 8(6), p. 325–326. doi: 10.1038/nrendo.2012.50.
• Jørgensen, Anders Palmstrøm; Ueland, Thor; Sode-Carlsen, Rasmus; Schreiner, Thomas; Rabben, Kai Fr. & Farholt, Stense [Show all 9 contributors for this article] (2010). Growth Hormone Treatment in Adults with Prader-Willi Syndrome Increases Bone Formative Markers, but Not Bone Resorption and Bone Mass: Results from a 12 Months Placebo-Controlled Study. Endocrine reviews. ISSN 0163-769X. 31(3).

View all works in Cristin